Antigen Binding Proteins That Bind ROR1
AssigneeSorrento Therapeutics, Inc.
InventorsHeyue Zhou, Xia Cao, Lucy Lu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides ROR1 binding proteins, particularly anti-ROR1 antibodies, or antigen-binding portions thereof, that specifically bind ROR1 and uses thereof. Various aspects of the anti-ROR1 antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-ROR1 antibodies. Methods for using the anti-ROR1 antibodies include in vitro and in vivo methods for binding ROR1, detecting ROR1 and treating diseases associated with ROR1 expression.
Claims50
An anti-ROR1 antigen-binding protein or fully human anti-ROR1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region,
- wherein the heavy chain variable region comprises a heavy chain complementarity determining region 1 (CDR1) a heavy chain CDR2 and a heavy chain CDR3, and the light chain variable region comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3;
- and
- (a) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:12, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:
- 13, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:
- 14, the light chain CDR1 has the amino acid sequence of SEQ ID NO:
- 15, the light chain CDR2 has the amino acid sequence of SEQ ID NO:
- 16, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:
- 17;
- (b) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:22, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:23, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:24, the light chain CDR1 has the amino acid sequence of SEQ ID NO:25, the light chain CDR2 has the amino acid sequence of SEQ ID NO:
- 26, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:27;
- (c) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:32, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:33, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:34, the light chain CDR1 has the amino acid sequence of SEQ ID NO:35, the light chain CDR2 has the amino acid sequence of SEQ ID NO:
- 36, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:37;
- (d) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:42, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:43, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:44, the light chain CDR1 has the amino acid sequence of SEQ ID NO:45, the light chain CDR2 has the amino acid sequence of SEQ ID NO:
- 46, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:47;
- (e) the heavy chain CDR1 has the amino acid sequence of SEQ ID NO:42, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO:43, the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:44, the light chain CDR1 has the amino acid sequence of SEQ ID NO:55, the light chain CDR2 has the amino acid sequence of SEQ ID NO:
- 56, and the light chain CDR3 has the amino acid sequence of SEQ ID NO:57.
An antigen-binding protein or fully human anti-ROR1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:10, 20, 30 or 40, and the light chain variable region having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:
- 11, 21, 31, 41 or 51.
An antigen-binding protein or fully human anti-ROR1 antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise the amino acid sequences of SEQ ID NOS:
- 10 and 11, respectively (e.g., herein called RO6D8-s10), SEQ ID NOS:
- 20 and 21, respectively (e.g., herein called RO6D8-jlv1011), SEQ ID NOS:
- 30 and 31, respectively (e.g., herein called RO6D8-011), SEQ ID NOS:
- 40 and 41, respectively (e.g., herein called RO6A-a7gm), or SEQ ID NOS:
- 40 and 51, respectively (e.g., herein called RO6A-a8gm).
The antigen-binding protein, antibody or antigen-binding fragment thereof, of any one of the preceding claims, comprising an IgG antibody, which is IgG1, IgG2, IgG3 or IgG4 class antibody.
The antigen-binding protein, antibody or antigen-binding fragment thereof, of any one of the preceding claims, wherein the antigen-binding protein, antibody, or the antigen-binding fragment thereof, binds human ROR1 protein with a KD of 10−7 M or less.
A pharmaceutical composition, comprising the antigen-binding protein, antibody or antigen-binding fragment of any one of the preceding claims and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.